FDA Accepts sNDAs for Expanded Use of HIV Therapies Pifeltro, Delstrigo

Officials with the FDA have accepted Merck’s supplemental New Drug Applications (sNDAs) to expand the use of doravirine (Pifeltro) and doravirine/lamivudine/tenofovir disoproxal fumarate (Delstrigo).
If approved, the new indication would allow treatment-experienced adults with HIV whose virus is suppressed to switch to doravirine in combination with other antiretroviral therapies (ARTs) or doravirine/lamivudine/tenofovir disoproxal fumarate, according to a Merck press release.
Doravirine 100 mg is a once-daily non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with other antiretroviral medicines. Doravirine (100 mg)/lamivudine (3TC, 300 mg)/tenofovir disoproxal fumarate (TDF, 300 mg) is a once-daily fixed-dose combination tablet indicated for the treatment of HIV in adults who have not previously been treated with ART.
The sNDA submissions were based on results from the phase 3 DRIVE-SHIFT trial evaluating the efficacy of switching to doravirine/3TC/TDF compared with continuing a baseline regimen of 2 NRTIs plus a boosted inhibitor, boosted elvitegravir, or NNRTI. According to the data, 670 patients who demonstrated virological suppression on an antiretroviral regimen for at least 6 months were randomized to receive either doravirine/3TC/TDF immediately on day 1 or after 24 weeks.
At 48 weeks, 90.8% of study participants who switched to doravirine/3TC/TDF on day 1 had HIV RNA <50 copies/mL compared with 94.6% of those who continued their baseline regimen. Additionally, 1.6% in the doravirine/3TC/TDF group had HIV RNA ≥50 copies/mL at week 48 compared with 1.8% of patients in the baseline regimen. Patients who switched to doravirine/3TC/TDF also showed statistically significant decreases in fasting LDL-cholesterol and non-HDL-cholesterol compared with those who continued on a boosted protease inhibitor regimen.
“Our clinical development program continues to generate meaningful evidence for Pifeltro and Delstrigo in people living with HIV,” Dr Michael Robertson, executive director and section head for HIV and HCV, Merck Research Laboratories, said in a statement. “We are pleased that the FDA has accepted these supplemental new drug applications. We look forward to continuing our work with the goal of expanding HIV treatment options.”
The Prescription Drug User Fee Act date for the sNDAs is September 20, 2019, according to Merck.
US FDA Accepts sNDAs for Pifeltro (doravirine) and Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) [news release]. Merck’s website. https://www.mrknewsroom.com/news-release/research-and-development-news/us-fda-accepts-sndas-pifeltro-doravirine-and-delstrigo-do. Accessed January 23, 2019.
Merck’s HIV Therapy DELSTRIGO (doravirine/lamivudine/tenofovir disoproxil fumarate) Meets Primary Efficacy Endpoint in Phase 3 DRIVE-SHIFT Study Evaluating Switch to DELSTRIGO from Other Antiretroviral Treatment Regimens [news release]. Merck’s website. https://www.mrknewsroom.com/news-release/corporate-news/mercks-hiv-therapy-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-. Accessed January 23, 2019.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

Pembrolizumab (Keytruda, Merck) is the first anti-PD-1 therapy approved in the adjuvant setting across patients with stage 3 melanoma.
Top news of the day across the health care landscape.
The supplemental Biologics License Application was filed based on positive overall survival data from a phase 3 clinical trial for pembrolizumab in the treatment of recurrent or metastatic head and neck squamous cell carcinoma.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.